Aegirbio is born out of diagnostics. The core activity is focused on the patient, and is about enabling patients to test themselves in various ways as simply and reliably as possible. The acquisition of Viraspec opened the door to rapid testing. More and more patients want to monitor themselves for signs of disease as a precautionary measure, or test for allergies, e.g., to certain foods. This appreciation has evolved into Aegirbio’s strategic focus on rapid tests. To ensure that patients can test themselves simply and reliably or take samples themselves and receive feedback from health professionals is the key to success in this area.
The Company has a clear vision of becoming an important global player in e-health. The path forward is trifold:
1: Over-the-counter rapid tests. The individual can quickly test himself for various diseases while traffic is generated on the Company's e-commerce platform.
2: Self-tests. Aegirbio wants to offer a platform where tests can be sent to the patient for at-home self-testing.
3: Medical feedback. In order to complete the offer, the Company must, either itself or via partners, provide follow-up of the test result through medically qualified personnel.
In conclusion, we want to create the real e-health company, which focuses entirely on the patient. The first building block of this construction was the launch of a rapid test for COVID-19. The next step was that we worked to launch a wider range of rapid tests, under the Qeurtest brand, during the summer. The idea is to create a shop-in-shop solution for the store, to make it easy for customers to find their tests. The next major step is the acquisition of Dynamic Code. Following the acquisition, Aegirbio's health-tech effort will be very comprehensive.
Dynamic Code is a healthtech company with its registered office in Linköping, offering diagnostic and health-test solutions to healthcare and directly to the consumer through a platform that combines physical tests with digital management. DNA technology and a digital platform for self-testing and diagnostics interconnect the patient, the healthcare provider, the pharmacy and the lab within an integrated system. The platform is fully scalable to healthcare operators and geographical regions.
Dynamic Code’s platform and product portfolio are unique and complement Aegirbio's activities. A merger gives both companies economies of scale with regard to product development, distribution and international expansion.
"The acquisition will kick-start our vision to become a global player in the rapidly evolving domain of e-health. Dynamic Code will be an important part of our multi-diagnostic company. We see a great potential in at-home testing now that more and more people are gaining an understanding and recognize the benefits of self-testing. We are currently looking at new interesting acquisition opportunities to further develop and consolidate ourselves as a leader in the field. Moreover, the new issue and loan gives us a strong cash position, which will enable us to realize our strategy to grow aggressively through acquisitions. I am proud and pleased with what we have achieved thus far and full of anticipation of what lies ahead,“ says Martin Linde, CEO of Aegirbio.
"Together, we can digitize diagnostics faster, with a broader product portfolio, and in more geographic markets. An important step to help people get control of their health more easily. The landscape of care is changing rapidly, and together we become an important international player to provide healthcare with better tools for diagnostics and preventive health,” says Anne Kihlgren, founder of Dynamic Code.
Anders Ingvarsson, COB, AegirBio AB
Telephone: +46 706 791 878
Martin Linde, CEO, AegirBio AB
Telephone: +46 706 730 968
AegirBio is a Swedish diagnostics company offering tests to monitor and optimize the dosing of biological drugs by means of a unique, patented technology platform. Biological therapies is the fastest growing segment of the pharmaceutical industry; a quarter of all drugs are projected to be biological in 2020. At the same time, drug concentrations vary tremendously (up to 100 times) in patients that receive biological drugs in standard doses.
The result of this one size fits all-approach is that patients with low drug concentrations do not respond to treatment, while excessive drug concentrations increase the risk of adverse effects in others. The uncertainty surrounding dosing results in overdosing or underdosing in about 55 percent of the cases, which causes unnecessary costs and suboptimal clinical outcomes.
The Company's tests for optimal dosing of biological drugs will be focused on neurological disorders, autoimmune diseases and cancer. In the first quarter of 2020, AegirBio initiated sales in the U.S. of the MoNATor test for the drug Tysabri, which is used for treatment of the neurological disorder Multiple Sclerosis (MS). AegirBio’s goal is to launch a total of four tests before 2023. Diagnostics will be offered through laboratory testing as well as in the form of a P.O.C. (Point of Care) test for use in hospitals and health centres. The plan further includes P.O.N. (Point of Need) tests for use at home.
For more information, please visit Aegirbio’s website, www.aegirbio.com
Certified adviser for the company is Eminova Fondkommission AB | +468-684 211 00 | firstname.lastname@example.org
This information is information that AegirBio AB is obliged to make public pursuant to the Nasdaq First North Growth Market rulebook. The information was submitted for publication, through the agency of the contact person set out above, at [●] a.m. CEST on June , 2021.